Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257465 · ClinicalTrials.gov registry record · Phase 1
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
A Phase 1 study of Melanoma, sponsored by AVAX Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 7
- Study locations
NCT00257465: Completed Phase 1 study of Melanoma, sponsored by AVAX Technologies.
NCT00257465 is a Phase 1 study of Melanoma that has completed, run by AVAX Technologies. The registered enrollment target is 82 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (88% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00257465, a Phase 1 study of Melanoma, has completed, sponsored by AVAX Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune response to patients' own cancer cells.
Conditions Studied
Interventions
- BIOLOGICAL Autologous, DNP-modified vaccine (M-Vax)
- BIOLOGICAL Autologous, DNP-Modified Melanoma Vaccine
- BIOLOGICAL Autologous, DNP-Modified Vaccine
Study Locations (7)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- Thomas Jefferson University - Philadelphia
Arizona
- University of Arizona Cancer Center - Tucson
California
- Pacific Oncology and Hematology Associates - San Diego
Illinois
- University of Illinois School of Medicine - Chicago
Kentucky
- University of Louisville - Louisville
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
What the finished NCT00257465 record still lists
NCT00257465 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Autologous, DNP-modified vaccine (M-Vax) is the first listed.
NCT00257465 lists 7 locations in 6 states (Pennsylvania, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT00257465 about?
NCT00257465 is a clinical study titled "Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma". The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune response to patients' own cancer cells.
What is the current status of trial NCT00257465?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2005-06. Estimated completion is 2008-06.
What conditions does trial NCT00257465 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00257465?
The interventions under investigation include: Autologous, DNP-modified vaccine (M-Vax) (BIOLOGICAL), Autologous, DNP-Modified Melanoma Vaccine (BIOLOGICAL), Autologous, DNP-Modified Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00257465?
This trial is sponsored by AVAX Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00257465 being conducted?
This trial has 7 study locations across Arizona, California, Illinois, Kentucky, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00257465's enrollment target sits among peer trials
82 127th of 266 higher than 140 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia